- Home
- FRME vs AUPH Comparison
FRME vs AUPH Comparison
Compare FRME & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRME | AUPH |
|---|---|---|
| Founded | 1893 | 1993 |
| Country | United States | Canada |
| Employees | 2086 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | FRME | AUPH |
|---|---|---|
| Price | $43.54 | $15.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $48.33 | $17.25 |
| AVG Volume (30 Days) | 419.4K | ★ 1.8M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.62% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | $27.67 | $17.54 |
| Revenue Next Year | $5.91 | $15.74 |
| P/E Ratio | ★ $10.90 | $63.20 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $34.66 | $7.36 |
| 52 Week High | $44.50 | $19.25 |
Technical Indicators
Market Signals| Indicator | FRME | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 62.52 | 42.33 |
| Support Level | $40.53 | $14.37 |
| Resistance Level | N/A | $16.07 |
| Average True Range (ATR) | 1.10 | 0.84 |
| MACD | 0.23 | -0.14 |
| Stochastic Oscillator | 74.20 | 8.25 |
Price Performance
Historical ComparisonAbout FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment, which is community banking.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.